Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 0.59 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107 | 1.00 | TAAR1 (1.00) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| SCHEMBL240503 | 1.00 | TAAR1 (1.00) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| Bromide SCHEMBL29883460 | 0.97 | TAAR1 (0.95) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| Bromide SCHEMBL28358414 | 0.97 | TAAR1 (0.95) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| Hydrochloric Acid SCHEMBL337907 | 0.97 | TAAR1 (0.95) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| SCHEMBL1930994 | 0.91 | TAAR1 (0.83) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| SCHEMBL28569127 | 0.91 | TAAR1 (0.83) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| Bicarbonate SCHEMBL9490583 | 0.91 | TAAR1 (0.83) | TAAR1HTR2AAOC3TRPA1 | |
| SCHEMBL28569125 | 0.91 | TAAR1 (0.83) | TAAR1HTR2AAOC3TRPA1RIPK1 | |
| Ammonia Solution, Strong SCHEMBL8416958 | 0.87 | TAAR1 (0.76) | TAAR1HTR2AAOC3TRPA1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118946165-A | Interface interaction spin-photon conversion body heterostructure and preparation method | 武汉大学 | 2024-11-12 | — | — | CN | claimed |
| CN-111362809-B | Chiral perovskite nanosheet, and preparation method and application thereof | 国家纳米科学中心 | 2023-03-31 | — | — | CN | claimed |
| CN-111362809-A | Chiral perovskite nanosheet, and preparation method and application thereof | 国家纳米科学中心 | 2020-07-03 | — | — | CN | claimed |
| US-8487131-B2 | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-07-16 | — | — | US | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | claimed |
| CN-1558898-A | Antiviral agent | ��Ұ����ҩ��ʽ���� | 2004-12-29 | — | — | CN | claimed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
| EP-4308168-B1 | METHODS FOR PREPARING CYCLOOCTENES AND CONJUGATES THEREOF | TAGWORKS PHARMACEUTICALS B V (NL) | 2026-05-20 | — | — | EP | disclosed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20250368633-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | ARTIVILA BIOPHARMA (CN) | 2025-12-04 | — | — | US | disclosed |
| CN-120967513-A | One-dimensional bismuth-based chiral perovskite crystal and preparation method and application thereof | 河南省科学院半导体研究所 | 2025-11-18 | — | — | CN | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| EP-0924193-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| WO-1999026927-A2 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5811293-A | CULTURE PRODUCT AS CHEMICAL INTERMEDIATE FOR ANTI-OBESITY AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| US-5629200-A | MICROORGANISM | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0654534-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-24 | — | — | EP | disclosed |
| US-5187165-A | Eseroline derivatives; cholinergic agents; antidepressants | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368633-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | RIPK1, RIPK2, RIPK4 | TAAR1 4751/4885HTR2A 3710/4885AOC3 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.